Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer

Figure 3

Development of a prognostic signature based on IRGPs in the TCGA-testing set. (a) Distribution of risk scores based on IRGPs in bladder patients; (b) survival status of patients in different groups; (c) heatmap of expression profiles of IRGPs; (d) survival analysis for the signature-defined risk groups; (e) time-dependent ROC curve of the 37-IRGPs prognostic signature.

(a)

(b)

(c)

(d)

(e)